Live Analyst Rating Changes 35281 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Myles Minter
WB

Myles Minter

William Blair
Wall Street Analyst
★★★☆☆
#1674
on 13Foresight · ranked by our own returns
47%
Success Rate
+5.2%
Average Return
50 of 107 calls profitable · +23.9% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 47% of Myles Minter's ratings turned a profit when each position was held for 1 year — averaging +5.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

222 Buy 56 Hold 0 Sell
Myles's Stock Coverage 33 ratings · 2026-09-28
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
ARCT
Arcturus Therapeutics
 Sep 24, 2026 BUY Buy
+120.0% avg upside
36 analysts
 — -1.9% ·
RAPP
Rapport Therapeutics, Inc.
 Sep 23, 2026 BUY Strong Buy
+72.0% avg upside
14 analysts
 — -2.4% ·
CTNM
Contineum Therapeutics, Inc. Class A
 Sep 23, 2026 BUY Strong Buy
+68.9% avg upside
9 analysts
 — +0.4% ·
VTGN
VistaGen Therapeutics
 Sep 23, 2026 HOLD Hold
+856.0% avg upside
8 analysts
 — -27.0% ·
IONS
Ionis Pharmaceuticals
 Sep 22, 2026 BUY Strong Buy
+69.3% avg upside
43 analysts
 — -2.7% ·
VRTX
Vertex Pharmaceuticals
 Sep 22, 2026 BUY Strong Buy
-15.5% avg upside
62 analysts
 — +2.2% ·
DNTH
Dianthus Therapeutics
 Sep 18, 2026 BUY Strong Buy
+13.6% avg upside
31 analysts
 — -8.5% ·
XENE
Xenon
 Sep 18, 2026 BUY Strong Buy
+52.9% avg upside
28 analysts
 — -1.9% ·
SLN
Silence Therapeutics
 Sep 10, 2026 BUY Buy
+211.6% avg upside
10 analysts
 — -8.0% ·
IMUX
Immunic
 Sep 10, 2026 BUY Strong Buy
+311.6% avg upside
22 analysts
 — -21.1% ·
BHVN
Biohaven Ltd.
 Sep 09, 2026 HOLD Buy
+76.2% avg upside
25 analysts
 — -14.7% ·
MRNA
Moderna
 Aug 19, 2026 BUY Hold
-48.0% avg upside
38 analysts
 — +14.1% ·
CAMP
CAMP4 Therapeutics Corporation
 Aug 14, 2026 BUY Strong Buy
+153.5% avg upside
9 analysts
 — -23.2% ·
NMRA
Neumora Therapeutics, Inc.
 Aug 14, 2026 BUY Buy
+1023.9% avg upside
11 analysts
 — -57.6% ·
ANRO
Alto Neuroscience, Inc.
 Aug 13, 2026 BUY Strong Buy
+20.5% avg upside
13 analysts
 — -17.0% ·
OVID
Ovid Therapeutics
 Aug 13, 2026 BUY Strong Buy
+116.4% avg upside
18 analysts
 — -10.9% ·
BBIO
BridgeBio Pharma
 Aug 11, 2026 BUY Strong Buy
+45.4% avg upside
34 analysts
 — -19.6% ·
AXSM
Axsome Therapeutics
 Aug 10, 2026 BUY Strong Buy
+21.6% avg upside
30 analysts
 — -11.7% ·
ALEC
Alector
 Aug 07, 2026 HOLD Hold
+410.0% avg upside
15 analysts
 — +8.4% ·
DNLI
Denali Therapeutics
 Aug 07, 2026 BUY Strong Buy
+90.1% avg upside
24 analysts
 — -17.6% ·
NTLA
Intellia Therapeutics
 Aug 06, 2026 BUY Buy
+219.2% avg upside
37 analysts
 — +4.5% ·
KRRO
Korro Bio
 Aug 06, 2026 BUY Strong Buy
+184.2% avg upside
19 analysts
 — -21.0% ·
LRMR
Larimar Therapeutics
 Aug 05, 2026 BUY Strong Buy
+477.4% avg upside
22 analysts
 — -25.0% ·
TRDA
Entrada Therapeutics Inc
 Aug 05, 2026 BUY Strong Buy
+248.0% avg upside
10 analysts
 — -12.8% ·
NBIX
Neurocrine
 Jul 31, 2026 BUY Strong Buy
+35.2% avg upside
37 analysts
 — -15.8% ·
ALNY
Alnylam Pharma
 Jul 30, 2026 BUY Strong Buy
+24.4% avg upside
51 analysts
 — +22.3% ·
BIIB
Biogen
 Jul 29, 2026 BUY Strong Buy
+12.1% avg upside
53 analysts
 — +8.8% ·
ARGX
Argenx Se
 Jun 24, 2026 BUY Strong Buy
-13.5% avg upside
48 analysts
 — +12.7% ·
VERX
Vertex
 Mar 31, 2026 BUY Buy
+190.3% avg upside
24 analysts
 — +1.6% ·
OKUR
OnKure Therapeutics
 Dec 22, 2023 HOLD Buy
+672.3% avg upside
13 analysts
 — -38.4% ·
NEUP
Neuphoria Therapeutics
 Sep 28, 2023 BUY Strong Buy
+450.0% avg upside
6 analysts
 — -81.0% ·
PRAX
Praxis Precision Medicines
 Mar 03, 2023 HOLD Strong Buy
+98.7% avg upside
24 analysts
 — · ·
NERV
Minerva Neurosciences
 Dec 29, 2022 HOLD Strong Buy
+146.3% avg upside
8 analysts
 — +307.3% ·
🔒 28 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Myles Minter — Frequently Asked Questions
How accurate are Myles Minter's stock ratings?
Based on the calls 13Foresight could measure, about 47% of Myles's ratings were profitable over a one-year hold, with an average return of +5.2% per rating, or +23.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Myles ranked on 13Foresight?
Myles Minter is currently ranked #1674 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Myles cover?
Myles most recently has ratings on ARCT, RAPP, CTNM, VTGN, IONS, VRTX, DNTH, XENE, SLN, IMUX, BHVN, MRNA and 21 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.